Chest
DIAGNOSIS AND MANAGEMENT OF LUNG CANCER: ACCP GUIDELINES (2ND EDITION)Treatment of Non-small Cell Lung Cancer, Stage IV: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition)
Section snippets
Materials and Methods
In light of the recommendations made in 2003, additional questions that were believed to be pertinent to patients with advanced stage IIIB/IV NSCLC were asked. A systematic review of the literature was undertaken by the multidisciplinary writing committee to identify published materials, including both original articles and guidelines, that address lung cancer diagnosis, management, and treatment. Materials that are appropriate to this topic were obtained by literature search of a computerized
Is There an Advantage to Using Three Chemotherapeutic Agents Compared With Two in Patients With Stage IV NSCLC and Good PS?
The 2003 ACCP recommendations defined platinum-based doublets as the standard of care for patients with stage IV NSCLC and good PS.3 Delbaldo et al4 reported a metaanalysis that included 13,601 patients in 65 trials and showed that two chemotherapeutic agents led to superior response and survival rates in patients with stage IV NSCLC compared with single agents (Table 2). Since the report of that metaanalysis, platinum-based doublets were shown to be superior to single-agent therapy in three
Recommendations
1. In patients with stage IV NSCLC and good PS, two-drug combination chemotherapy is recommended. The addition of a third cytotoxic chemotherapeutic agent is not recommended because it provides no survival benefit and may be harmful. Grade of recommendation, 1A
2. Bevacizumab improves survival combined with carboplatin and paclitaxel in a clinically selected subset of patients with stage IV NSCLC and good PS (nonsquamous histology, lack of brain metastases, and no hemoptysis). In these patients,
Recommendations
3. In patients who have stage IV NSCLC and are elderly (≥ 70 to 79 years old), single-agent chemotherapy is recommended for most. Grade of recommendation, 1A
4. However, in patients who have stage IV NSCLC, are elderly (≥ 70 to 79 years old), have good PS, and lack significant comorbidities, two-drug combination chemotherapy is recommended as an option. Grade of recommendation, 1B
5. In patients who have stage IV NSCLC and are ≥ 80 years old, the benefit of chemotherapy is unclear and should be
Recommendations
6. In patients with stage IV NSCLC and a PS of 2, chemotherapy is recommended on the basis of defined response rates and symptom palliation. Grade of recommendation, 1B
7. In patients with stage IV NSCLC and a PS of 2, no specific recommendation can be given with regard to the optimal chemotherapeutic strategy. A single phase III trial showed a survival benefit to a carboplatin-based doublet compared with a single agent in a prospectively planned subset analysis. Grade of recommendation, 2C
Recommendation
8. It is recommended that patient-reported HRQOL be measured using the FACT-L or EORTC QLQ-C30 questionnaire because it is a significant prognostic factor for survival. Grade of recommendation, 1A
Recommendation
9. It is recommended that patients with stage IV NSCLC receive adequate education about the risks and benefits of chemotherapy to enable active participation in the decision-making process regarding treatment selection. Grade of recommendation, 1C
Conclusions
The standard of care for the treatment of the patient with stage IV NSCLC and good PS remains doublet-based therapy, with the exception of patients who are eligible to receive bevacizumab, which has been shown in a large, randomized, phase III trial to improve survival over chemotherapy alone. Elderly patients (≥ 70 to 79 years old) also benefit from therapy, as do patients with poor PS. These populations are heterogeneous, and the optimal approach in these patients remains controversial and
References (81)
- et al.
Chemotherapeutic management of stage IV non-small cell lung cancer
Chest
(2003) - et al.
Role of chemotherapy in patients with poor performance status and advanced non-small cell lung cancer
Semin Oncol
(2004) Treatment of patients with advanced lung cancer and poor performance status
Clin Lung Cancer
(2004)- et al.
Clinical-benefit response in advanced non-small-cell lung cancer: a multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine
Ann Oncol
(2001) - et al.
Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy
Lung Cancer
(1999) - et al.
The patient's perception of his own quality of life might have an adjunctive prognostic significance in lung cancer
Lung Cancer
(1995) - et al.
Symptom distress in newly diagnosed ambulatory cancer patients and as a predictor of survival in lung cancer
J Pain Symptom Manage
(1995) - et al.
Prognostic factors for patients with inoperable non-small cell lung cancer, limited disease: the importance of patients' subjective experience of disease and psychosocial well-being
Radiother Oncol
(1989) - et al.
Quality of life in lung cancer surgical adjuvant trials
Chest
(1994) - et al.
The prognostic impact of quality of life assessed with the EORTC QLQ-C30 in inoperable non-small cell lung carcinoma treated with radiotherapy
Radiother Oncol
(2000)
Quality of life in lung cancer patients: as an important prognostic factor
Lung Cancer
Significant progress in palliative treatment of non-small cell lung cancer in the past decade
Chest
Cancer patients' attitudes toward treatment options for advanced non-small cell lung cancer: implications for patient education and decision support
Patient Educ Couns
Do doctors know when their patients don't? A survey of doctor-patient communication in lung cancer
Lung Cancer
Communicating the diagnosis of lung cancer
Respir Med
Who gets chemotherapy for metastatic lung cancer?
Chest
Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer
Lung Cancer
Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer
Ann Oncol
Vinorelbine plus cisplatin versus cisplatin plus vindesine and mitomycin C in stage IIIB-IV non-small cell lung carcinoma: a prospective randomized study
Lung Cancer
Clinical presentation and diagnosis
Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis
JAMA
Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the Cancer and Leukemia Group B (study 9730)
J Clin Oncol
Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter phase III trial
J Clin Oncol
Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group
J Clin Oncol
Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group
J Clin Oncol
Adding gemcitabine to paclitaxel/carboplatin combination increases survival in advanced non-small-cell lung cancer: results of a phase II–III study
J Clin Oncol
Cisplatin plus gemcitabine (CG) vs a cisplatin-based triplet vs nonplatinum sequential doublets in advanced non-small cell lung cancer (NSCLC): a Spanish Lung Cancer Group phase III randomized trial (GEPC/98-02)
J Clin Oncol
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial; INTACT 1
J Clin Oncol
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer
J Clin Oncol
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial; INTACT 2
J Clin Oncol
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
N Engl J Med
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer
J Clin Oncol
Influence of extent of disease, histology, and demographic factors on lung cancer survival in the SEER population-based data
Semin Surg Oncol
Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from Surveillance, Epidemiology and End Results-Medicare
J Clin Oncol
Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer
J Clin Oncol
Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer: the Elderly Lung Cancer Vinorelbine Italian Study Group
J Natl Cancer Inst
Randomized phase III study of docetaxel (D) versus vinorelbine (V) for elderly patients (pts) with advanced non-small cell lung cancer (NSCLC): results of a West Japan Thoracic Oncology Group trial (WJTOG9904)
J Clin Oncol
Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer
J Clin Oncol
Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial
J Natl Cancer Inst
Cited by (172)
Cancer of the Lung: Non-Small Cell Lung Cancer and Small Cell Lung Cancer
2019, Abeloff’s Clinical OncologyCirculating tumor cells dynamics during chemotherapy predict survival and response in advanced non-small-cell lung cancer patients
2023, Therapeutic Advances in Medical OncologyLong-term Surgical Outcomes in Oligometastatic Non-small Cell Lung Cancer: A Single-Center Study
2023, Journal of Chest Surgery
The authors have reported to the ACCP that no significant conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/misc/reprints.shtml)